Alpelisib is an oral phosphatidylinositol-3-kinase (PI3K) inhibitor. Its mechanism of action is to block the activity of PI3K enzymes, inhibit the proliferation and spread of tumor cells, and simultaneously induce the apoptosis of breast cancer cells.
Authentic
Guarantee
Fast Delivery
Privacy Alpelisib has relatively many adverse reactions. If not detected and treated promptly and correctly, these can have a significant impact on the patien···【More】
Update: 23 Mar,2026Source: BigbearViews: 220
Efficacy and Actions of ElacestrantElacestrant is an anti-tumor drug, belonging to the estrogen receptor antagonist class.Efficacy and Actions of Elac···【More】
Update: 18 Mar,2026Source: BigbearViews: 193
Precautions for Axitinib UseAxitinib is an oral, highly selective tyrosine kinase inhibitor developed by Pfizer, primarily used to treat advanced rena···【More】
Update: 18 Mar,2026Source: BigbearViews: 186
Dificid's Efficacy and ActionsDificid was developed by Astellas Pharma in Japan and approved by the US FDA on May 27, 2011.Dificid is a fermentati···【More】
Update: 18 Mar,2026Source: BigbearViews: 189
Apellixis is a targeted therapy for a specific type of breast cancer, developed by Novartis in Switzerland and approved by the US FDA in 2019.Precauti···【More】
Update: 18 Mar,2026Source: BigbearViews: 186
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos